Clinical Research Directory
Browse clinical research sites, groups, and studies.
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
Sponsor: City of Hope Medical Center
Summary
RATIONALE: Gathering information from patients of different ages receiving paclitaxel albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors understand how the age of the patient changes the way the drug works. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients of different ages with metastatic breast cancer.
Official title: Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics
Key Details
Gender
All
Age Range
18 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2008-02-11
Completion Date
2026-04-24
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Interventions
paclitaxel albumin-stabilized nanoparticle formulation
100 mg/m2 3 weeks on 1 week off
pharmacological study
Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
physiologic testing
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
questionnaire administration
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
study of socioeconomic and demographic variables
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
cognitive assessment
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
psychosocial assessment and care
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Locations (2)
City of Hope Medical Center
Duarte, California, United States
City of Hope Medical Group
Pasadena, California, United States